12 Best Low Price Pharma Stocks To Invest In Right Now

3. Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Share Price as of the Close of February 21: $7.83

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) develops and distributes affordable generic and specialty drugs, including key diabetes treatments. Its products include the recently FDA-approved GLP-1 agonist exenatide, which is used to treat type 2 diabetes, and generic metformin, which is a first-line treatment for the disease. Advanced, reasonably priced therapeutic solutions are made possible by the company’s concentration on complicated generics.

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) announced a 13% increase in net revenue to $702 million in Q3 2024, which was a solid result. Neurology and endocrinology drugs drove a 19% increase in specialty sales, while generics revenue increased by 9%. Adjusted EPS came at $0.165, and adjusted EBITDA increased by 2% to $158 million. Due to the success of new products, biosimilars, and generics, the company has made $2.68 billion so far this year. The company is concentrating on high-margin products to increase profitability, even if its GAAP net loss was only $0.2 million.

Metsera, Inc. and Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) have partnered together to create next-generation therapies for metabolic disorders and obesity. Amneal’s network and facilities will help Metsera’s injectable and oral initiatives, which include GLP-1 and amylin receptor agonists. To improve its market position, the business has also resubmitted its New Drug Application for the DHE Autoinjector, aims to introduce CREXONT for Parkinson’s disease, and purchased a high-value biosimilar. The company’s dedication to expansion and innovation in the pharmaceutical sector is demonstrated by these projects as well as its emphasis on specialized and complex generic medications.

Analysts hold a consensus Strong Buy rating on Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) and it stands third among the best low-price pharma stocks to invest in right now.